US FDA clarifies on registration requirements for IRBs
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration, responding to reports of “some confusion” within the institutional review board community, has issued a clarification regarding the registration of IRBs recurrently reviewing FDA-regulated products1.